Alec Machiels is Director at Apellis Pharmaceuticals, Inc. (APLS). They have made 32 open-market trades across 1 company since 2020, most recently 2026-01-01.
CIK 0001496687
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 32 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| APLS | SELL · 10b5-1 | 2023-11-17 | 2023-11-20 | $47.74 | $60K | +25.4% | +11.9% | +38.1% |
| APLS | SELL · 10b5-1 | 2023-10-17 | 2023-10-18 | $48.50 | $61K | +4.7% | +7.3% | +44.8% |
| APLS | SELL · 10b5-1 | 2023-09-18 | 2023-09-19 | $45.00 | $56K | -21.1% | -4.2% | +16.1% |
| APLS | SELL · 10b5-1 | 2023-09-15 | 2023-09-18 | $45.34 | $113K | -22.2% | -9.7% | +9.8% |
| APLS | SELL · 10b5-1 | 2023-07-17 | 2023-07-18 | $64.79 | $162K | -19.7% | -22.5% | +20.8% |
| APLS | SELL · 10b5-1 | 2023-06-20 | 2023-06-21 | $88.41 | $221K | +3.1% | -60.2% | -44.2% |
| APLS | SELL · 10b5-1 | 2023-05-17 | 2023-05-18 | $88.66 | $111K | -2.9% | -0.3% | -64.7% |
| APLS | SELL · 10b5-1 | 2023-04-17 | 2023-04-18 | $81.05 | $203K | +2.2% | +7.2% | -35.7% |
| APLS | SELL | 2023-03-17 | 2023-03-21 | $64.03 | $160K | +7.5% | +34.4% | +43.7% |
| APLS | SELL | 2023-02-17 | 2023-02-21 | $52.38 | $65K | +7.0% | +4.1% | +44.0% |
| APLS | SELL | 2023-01-17 | 2023-01-19 | $52.42 | $66K | +1.5% | +12.6% | +58.0% |
| APLS | SELL | 2022-12-15 | 2022-12-19 | $52.35 | $131K | +0.4% | -0.1% | +22.4% |
| APLS | SELL | 2022-11-15 | 2022-11-17 | $48.01 | $120K | +3.5% | +7.9% | +9.8% |
| APLS | SELL | 2022-10-14 | 2022-10-17 | $59.31 | $148K | -1.1% | -26.9% | -13.2% |
| APLS | SELL | 2022-09-15 | 2022-09-16 | $66.00 | $83K | +0.7% | -6.6% | -16.2% |
| APLS | SELL | 2022-08-15 | 2022-08-16 | $67.21 | $168K | -17.9% | -4.8% | -31.1% |
| APLS | SELL | 2022-07-15 | 2022-07-18 | $46.33 | $116K | +1.6% | +21.7% | +3.5% |
| APLS | SELL · 10b5-1 | 2022-06-15 | 2022-06-17 | $39.29 | $49K | +1.0% | -0.1% | +44.6% |
| APLS | SELL · 10b5-1 | 2022-05-16 | 2022-05-17 | $39.18 | $49K | +4.0% | +4.6% | +67.5% |
| APLS | SELL | 2022-04-14 | 2022-04-18 | $50.90 | $64K | -12.2% | -14.9% | -12.4% |
| APLS | SELL · 10b5-1 | 2022-03-15 | 2022-03-17 | $39.57 | $49K | +4.0% | +9.8% | -12.1% |
| APLS | SELL | 2022-02-15 | 2022-02-16 | $45.43 | $114K | -2.6% | +15.2% | -8.2% |
| APLS | SELL | 2022-01-14 | 2022-01-19 | $40.56 | $51K | +6.0% | +12.4% | +37.5% |
| APLS | SELL | 2021-12-15 | 2021-12-17 | $42.88 | $257K | +3.7% | -16.9% | +1.3% |
| APLS | SELL | 2021-11-04 | 2021-11-17 | $39.25 | $236K | -6.3% | +5.0% | +4.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.